Samuel Kintz Sells 1,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Key Points

• Enliven Therapeutics CEO Samuel Kintz sold 1,000 shares of stock on September 19th for a total of $20,250, resulting in a 0.11% decrease in his ownership.
• The company's stock price fell by $0.96 during midday trading, closing at $18.96, with significant trading volume of 2,310,053 shares.
• Analysts have given Enliven Therapeutics an average Buy rating with a target price of $41.20, notably with recent upgrades from HC Wainwright and Robert W. Baird.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 1,000 shares of the firm's stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $20.25, for a total value of $20,250.00. Following the completion of the transaction, the chief executive officer directly owned 921,892 shares in the company, valued at $18,668,313. The trade was a 0.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $19.09, for a total value of $95,450.00.
• On Tuesday, August 19th, Samuel Kintz sold 590 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $11,800.00.
• On Monday, August 18th, Samuel Kintz sold 10,393 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.02, for a total value of $208,067.86.
• On Thursday, July 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.52, for a total value of $281,500.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN traded down $0.96 during trading on Friday, hitting $18.96. The company had a trading volume of 2,310,053 shares, compared to its average volume of 523,887. The stock has a 50 day simple moving average of $20.11 and a 200 day simple moving average of $19.66. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The firm has a market capitalization of $1.12 billion, a P/E ratio of -9.48 and a beta of 0.89.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. As a group, analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ELVN shares. Robert W. Baird raised their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 16th. The Goldman Sachs Group started coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 price objective on the stock. Finally, HC Wainwright raised their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $41.20.

Institutional Trading of Enliven Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameriprise Financial Inc. acquired a new stake in Enliven Therapeutics during the fourth quarter worth about $789,000. Millennium Management LLC boosted its position in Enliven Therapeutics by 108.6% during the fourth quarter. Millennium Management LLC now owns 50,804 shares of the company's stock worth $1,143,000 after purchasing an additional 26,449 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Enliven Therapeutics by 67.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock worth $984,000 after purchasing an additional 17,546 shares in the last quarter. Rhumbline Advisers boosted its position in Enliven Therapeutics by 4.9% during the first quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock worth $1,033,000 after purchasing an additional 2,466 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in Enliven Therapeutics during the fourth quarter worth approximately $112,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.